Anesiva, Inc.

Anesiva, Inc. is a biopharmaceutical company focused on developing products that enhance pain management and dietary support, particularly for cardiovascular health, through innovative solutions for healthcare providers and patients. Founded in 1999 in South San Francisco, US, Anesiva, Inc. specializes in biopharmaceuticals aimed at pain management and cardiovascular health.

The company underwent significant changes in its operations in 2004 and has secured a total of USD 25. 00 mn in funding from investors including Alta Partners. Anesiva has completed a total of 3 deals, with its most recent deal taking place on February 12, 2004. The company raised USD 96.

00 mn in an IPO in October 2003, selling 6 million shares at USD 16 per share. Anesiva is primarily focused on developing innovative biopharmaceutical products aimed at enhancing pain management and diet management. Its flagship product, Nexletol, is designed to support dietary management by addressing cholesterol levels, thereby targeting conditions related to cardiovascular health. The company also offers other products, such as Zingo, a needle-free device for delivering medication that is tailored for pediatric patients, reducing anxiety associated with injections.

Anesiva's customer base includes healthcare providers, hospitals, and patients, predominantly in the United States and select international markets. By providing effective solutions to pressing medical needs, Anesiva aims to improve patient outcomes and overall quality of life. In the most recent year, 2008, Anesiva reported a revenue of USD 304,000, with an EBITDA of USD -47,451,000. The company generates revenue through partnerships with healthcare institutions and direct sales of its pharmaceutical products, engaging primarily in B2B transactions with hospitals and healthcare providers.

Anesiva plans to utilize recent funding to expand its product offerings and enter new markets. There are ongoing developments aimed at enhancing its product pipeline, particularly in pain management and dietary solutions, although specific product release dates have not been disclosed. The company is targeting expansions primarily in North America and Europe by 2005 to reach a broader patient base. Recent funding will support these initiatives and assist in increasing the company's production capabilities.